# Replimune Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/replimune-group

- Industry: Biotechnology
- Headquarters: Woburn, US
- Website: www.replimune.com
- Total disclosed funding: $85M
- Latest round: Series B (Sep 8, 2017)
- Investors on record: 8

## About

Replimune Group, Inc. is a US-based biotechnology company that develops innovative oncolytic immunotherapies, focusing on delivering targeted cancer treatments to improve patient outcomes.Founded in 2015 and headquartered in Woburn, US, Replimune specializes in oncolytic immunotherapy for cancer treatment. The company has undergone notable funding rounds, including a Private Placement/Follow on in December 2022, raising USD 225.00 mn, marking the total amount raised at USD 225.00 mn. The CEO, Philip Astley-Sparke, has a significant background in the biotech sector, which informs the company’s strategic direction.Replimune specializes in developing innovative oncolytic immunotherapies aimed at addressing the complexities of cancer treatment. Their core product offerings include RP1 and RP2, designed to locally target tumors while simultaneously modulating the tumor microenvironment to elicit robust systemic immune responses. These therapies are being tested across various clinical trials addressing a range of solid tumor cancers, including melanoma, liver cancer, and non-melanoma skin cancers. Intended primarily for patients with difficult-to-treat malignancies, Replimune's therapies are undergoing evaluations both as standalone treatments and in combination with established immunotherapeutic agents like Nivolumab. The company's products primarily target markets in North America and Europe, focusing on healthcare providers, cancer treatment centers, and specialists who manage oncology patients.Replimune generates revenue through strategic partnerships and collaborations within the biopharmaceutical sector, focusing on clinical trial agreements and potential future licensing arrangements. Revenue transactions are structured around milestones associated with the development and commercialization of their investigational therapies. These agreements often involve payments contingent upon the achievement of specific clinical endpoints or regulatory approvals. While specific pricing details for their therapies have not been disclosed, the business model suggests a reliance on partnerships with healthcare systems and research institutions looking to incorporate advancements in cancer treatments into their offerings. As a result, future revenue streams may also include royalties or revenue-sharing agreements as their products advance through clinical development and into the commercial market.Replimune plans to utilize the recent funding from the Private Placement in December 2022 to generate human proof for its lead product RP1 and further develop its Immulytic platform for cancer treatment. The company will focus on launching their innovative therapies while expanding into new markets, specifically targeting additional regions in Europe and North America by 2024. Continued commitment to clinical trials will drive the advancement of their products, aligning with their objective to establish a stronger foothold in the biopharmaceutical landscape.

## Funding rounds

- Series B, Sep 8, 2017, $55M — Atlas Venture, Bain Capital, Forbion, Omega Funds, Leerink Partners, Foresite Capital, Redmile Group, Cormorant Asset Management
- Series A, Sep 24, 2015, $30M — Atlas Venture, Forbion, Omega Funds

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B
- Leerink Partners — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B